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Brief summary 41 
Among hospital-discharged older patients, besides comorbidities, unplanned rehospitalization 42 
at 6 months is associated with potentially inappropriate medications in home-discharged 43 
patients, with number of drugs in long term care facility-discharged patients. 44 
  45 
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Abstract  46 
Objectives: To evaluate whether STOPP/START v2 potentially inappropriate medications 47 
(PIMs) and potential prescribing omissions (PPOs) are associated with 6-month mortality and 48 
unplanned hospitalization in hospital-discharged older patients. 49 
Design: Multicenter prospective cohort observational study 50 
Setting and participants: patients aged ≥65 years consecutively discharged from acute 51 
geriatric and internal medicine wards of two university hospitals in North-western Italy 52 
Methods: At discharge, a comprehensive geriatric assessment was performed in each patient, 53 
prescribed medications were recorded, and PIMs and PPOs were determined according to 54 
STOPP/START v2. Death and unplanned readmissions at 6 months were investigated through 55 
telephone interviews; variables associated with outcomes were identified in the overall 56 
sample and according to discharge setting (i.e. home vs medium/long-term care facility, 57 
MLTCF) through a multivariate logistic regression model. 58 
Results: Among 611 patients (mean age 81.6 years, 48.4% females, 34.2% MLTCF-59 
discharged, mean number of drugs 7.7±3.2), with an inappropriate prescription (IP) 60 
prevalence at discharge of 71.7% (PIMs 54.8%, PPOs 47.3%), mortality and unplanned 61 
readmission rate were 25.0% and 30.9%. Neither PIMs nor PPOs were associated with 62 
overall mortality. A higher number of PIMs was significantly associated with unplanned 63 
readmission in the overall sample (OR 1.23, 95%CI 1.03-1.46), and in home-discharged 64 
patients (OR 1.38, 95%CI 1.13-1.68). The number of drugs at discharge was associated with 65 
readmissions in the overall sample (OR 1.11, 95%CI 1.05-1.18) and in MLTCF-discharged 66 
patients (OR 1.27, 95%CI 1.13-1.42). PPOs were not significantly associated with clinical 67 
outcomes. 68 
Conclusions and implications: In hospital-discharged polymorbid older patients, 6-month 69 
unplanned readmissions were associated with number of PIMs in home-discharged patients 70 
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and with number of drugs in MLTCF-discharged patients. This reaffirms the importance of 71 
performing a systematic and careful review of medication appropriateness in hospital-72 
discharged older patients. 73 
  74 
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INTRODUCTION 75 
The growing burden of polypathology is inherently associated with the prescription of 76 
complex polytherapies. Polypharmacy and inappropriate prescribing (IP) are well-known risk 77 
factors for adverse drug events (ADEs), frequently leading to unfavorable outcomes in older 78 
people 1–4. Balancing the needs to effectively treat multiple diseases and to avoid iatrogenic 79 
harm is complex in clinical practice 5,6. Indeed, under-prescription is tightly linked with over-80 
prescription, since polypharmacy may lead the prescriber to omit potentially beneficial 81 
medications 7, leading to increased morbidity and mortality 8. 82 
Different tools have been developed to identify IP and optimize pharmacotherapy in 83 
older patients. Despite being the first published and most widely used, the Beers criteria 9 84 
have restricted applicability in Europe and overlook important aspects of IP, such as 85 
duplicated prescriptions and potential prescribing omissions (PPOs) 10. Moreover, potentially 86 
inappropriate medications (PIMs) at discharge according to Beers criteria were not associated 87 
with short-time re-hospitalization or death 11,12. To overcome these limitations, a panel of 88 
European experts developed the Screening Tool of Older People’s Prescriptions and 89 
Screening Tool to Alert to Right Treatment (STOPP/START) criteria in 2008 13, which have 90 
been recently updated (STOPP/START v2) 14. They include a list of conditions in which 91 
specific drugs may represent a PIM (STOPP criteria) or a PPO (START criteria). 92 
While IP according to STOPP/START criteria can be regarded as a process measure of 93 
medication safety in older patients, it is important to establish its association with adverse 94 
outcomes in different clinical settings. Only a few studies have investigated this association 95 
so far, mainly retrospectively and focusing on PIMs, with inconsistent results. Indeed, PIMs 96 
according to STOPP criteria have been associated with ADEs 15–17 and functional decline 18. 97 
STOPP/START criteria application during hospitalization reduces ADEs 19, and the 98 
implementation of an educational program on IP for physicians working in nursing homes, 99 
6 
 
mainly focused on STOPP/START criteria, reduced the incidence of delirium and falls in a 100 
cluster-randomized multicenter trial [Garcia-Gollarte et al JAMDA 2014]. However, 101 
evidence on the impact of IP on hospitalization and mortality is scant and highly 102 
heterogeneous. PIMs identified according to STOPP criteria have been associated with higher 103 
morbidity, reduced quality of life and increased emergency department visits and hospital 104 
admissions 20–25. The impact of PPOs has been far less studied; single studies have reported 105 
an association with emergency department visits 21 and 4-year mortality 25. 106 
Since there is persistent uncertainty about clinical implications of IP in older medical 107 
in-patients, we designed a two-phase prospective observational study to evaluate the 108 
prevalence and potential clinical implications (death and unplanned readmissions) of IP 109 
according to STOPP/START v2 among hospital-discharged older patients. We have 110 
previously reported the results of the cross-sectional analysis 26, demonstrating a high 111 
prevalence of both PIMs and PPOs in this population; among other variables, a higher 112 
number of drugs at discharge was strongly associated with both PIMs and PPOs, whereas 113 
geriatric discharge was protective for both. In this paper, we report the results of the 114 
longitudinal part of the study, aimed to investigate the association of IP (including PIMs and 115 
PPOs) with overall mortality and unplanned hospital readmission among hospital-discharged 116 
older patients. 117 
METHODS 118 
The present study was carried out according to the Recommendations Guiding 119 
Physicians in Biomedical Research Involving Human Subjects, approved by the local ethics 120 
committee, and reported conforming to the Strengthening The Reporting of Observational 121 
Studies in Epidemiology statements 
27
. Signed informed consent was obtained by patients, or 122 
by proxies or caregivers for patients unable to express consent. 123 
Study design, setting and participants 124 
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A complete description of the study has been previously published 26. Briefly, patients 125 
aged ≥65 years consecutively discharged between March and June 2017 from three internal 126 
medicine and two geriatric wards of two teaching hospitals in North-western Italy were 127 
prospectively enrolled. Exclusion criteria were: in-hospital death, lack of informed consent, 128 
incomplete data, and previous enrolment. Demographic and clinical variables (age, sex, 129 
comorbidities, body weight and serum creatinine at enrolment to estimate glomerular 130 
filtration rate according to the Cockcroft–Gault formula), main diagnosis at discharge, 131 
discharge setting (home vs medium/long-term care facility, MLTCF), and number of 132 
prescribed medications were recorded. Polypharmacy was defined as ≥5 drugs, and excessive 133 
polypharmacy as >10 drugs 28. Comorbidities were grouped according to Cumulative Illness 134 
Rating Scale (CIRS) classes; the CIRS-Severity Index (CIRS-SI, the mean score of the first 135 
13 items), and the CIRS-Comorbidity Index (CIRS-CI, the number of items with a score ≥3) 136 
were calculated 33. As outcomes might be affected by disease severity, to better evaluate the 137 
impact of exposure as a result of drug–disease or drug–syndrome interaction, only CIRS 138 
classes with a score ≥3 were considered in the analysis. A Comprehensive Geriatric 139 
Assessment (CGA) was performed in each patient, including evaluation of functional 140 
dependence (Katz Index of activities of daily living – ADL 29, and instrumental ADL – IADL 141 
30), cognitive function (Short Portable Mental Status Questionnaire – SPMSQ 31) and frailty 142 
(CSHA scale 32). Patients were considered dependent in ADL with ≥3 lost functions, and 143 
partially or completely not autonomous in IADL with scores ≤9. Moderate to severe 144 
cognitive impairment was identified by SPMSQ scores ≥5. A CSHA score ≥5 identified frail 145 
patients, while a score of 9 identified terminally-ill patients, who were excluded from the 146 
analysis. In order to capture real-world clinical practice, physicians working in the hospital 147 
units involved were not aware about the study. 148 
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Exposure: potentially inappropriate medications and potential prescribing 149 
omissions 150 
STOPP/START v2 consist of 80 STOPP criteria and 34 START criteria, organized 151 
according to physiological system 14. PIMs at discharge were identified by applying the full 152 
list of STOPP v2 criteria. STOPP A category includes two implicit rules: “drugs prescribed 153 
without a clinical indication” and “drugs prescribed beyond the recommended duration”. 154 
Their application was evaluated case-by-case by two investigators, and implicated 155 
medications were recorded. PPOs were detected by applying START v2 criteria. Due to the 156 
setting of the study, potential indications to acetylcholinesterase inhibitors (START C3), eye 157 
drops for open angle glaucoma (START C4) and vaccines (START I) were not assessed. 158 
Furthermore, any laxative was considered as fiber supplement (START D2). 159 
Outcome variables 160 
The outcome variables were all-cause mortality and unplanned hospital readmission. 161 
Follow up at 6 months ± 6 weeks was carried out between September and December 2017 162 
through telephone interviews with patients or usual caregivers. Missing information was 163 
obtained from the hospital’s discharge database and register office. Whenever a telephone 164 
interview was not possible, or the patient withdrew his consent, the patient was considered as 165 
lost at follow-up. 166 
Statistical analysis 167 
Absolute and relative frequencies of dichotomous and categorical variables, and either mean 168 
and standard deviation (SD) or median and interquartile range (IQR) of continuous variables 169 
were calculated, as appropriate. The univariate association between outcomes and clinical 170 
characteristics, and differences among different groups of patients were evaluated using the 171 
Chi-square test for dichotomous and categorical variables, and ANOVA or Mann-Whitney 172 
test for normally distributed and not normally distributed continuous variables, respectively. 173 
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To identify variables independently associated with outcomes, a multivariate logistic 174 
regression analysis (stepwise method) was carried out, where PIMs and PPOs (considered as 175 
continuous variables), and all significant variables from univariate analysis were entered as 176 
independent variables, while death and unplanned readmission were the dependent variables. 177 
Potential interactions between presence of renal disease or moderate-severe cognitive 178 
impairment and PIMs, PPOs and/or number of drugs at discharge were investigated in 179 
multivariate models where the latter resulted significantly associated with outcomes. 180 
Adjusted odds ratios (OR) and their 95% confidence intervals (CI) were calculated. Statistical 181 
significance was set at P value < .05. Statistical analysis was carried out using MedCalc 182 
Statistical Software 9.3.7.0 (MedCalc Software BVBA, Ostend, Belgium). 183 
RESULTS 184 
Sample characteristics 185 
Of 1.119 patients discharged from the five participating wards during recruitment period, 186 
910 were aged ≥65 years and discharged alive; 34 (3.7%) of them refused to give informed 187 
consent. After exclusion of patients for whom complete data were not available (mainly body 188 
weight and SPMSQ), the baseline sample included 726 patients; its demographic and clinical 189 
characteristics, prevalence of and variables associated with IP have been previously reported 190 
26. Of patients enrolled at baseline, 49 (6.7%) were terminally-ill and 66 (9.1%) were lost at 191 
follow-up (Figure 1), leaving a sample of 611 patients for analysis. There were no significant 192 
differences in number and prevalence of PIMs and PPOs between patients lost at follow-up 193 
and the study sample (Supplementary Table S1). Table 1 shows the characteristics of study 194 
patients (mean age 81.6 years, 48.4% females), who had a high prevalence of functional 195 
dependence (71.4% in IADL and 48.7% in ADL), frailty (69.4%), and comorbidities (mean 196 
CIRS comorbidity index 4.7±1.6, chronic renal disease in 38.5%, moderate-severe cognitive 197 
impairment in 28.5%); 65.8% of patients were discharged at home and 34.2% in MLTCF. 198 
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These latter were significantly older, more frequently frail and functionally dependent, and 199 
showed a higher comorbidity burden, with higher prevalences of moderate-severe cognitive 200 
impairment (46.4% vs 19.2%, p <0.001) and other neurological comorbidities (e.g., history of 201 
stroke, seizures, intracranial masses, 29.2% vs 17.2%, p < 0.001, and psychiatric and 202 
behavioral diseases, including dementia, 49.8% vs 28.9%, p < 0.001). At discharge, 4,683 203 
prescribed medications were recorded, with a mean of 7.7±3.2 prescribed medications per 204 
patient. Overall, 1,036 IPs were recorded, with PIMs being more frequent than PPOs (580 vs 205 
456, respectively). At least one IP was observed in 71.7% of patients; 54.8% and 47.3% of 206 
patients had at least one PIM and PPO, respectively, with multiple IP being frequent (Figure 207 
2). A full list of recorded PIMs and PPOs and their prevalence is reported as Supplementary 208 
Table S2. Patients discharged with at least one IP showed a higher comorbidity burden, IADL 209 
dependence and number of drugs at discharge, compared with patients without IP 210 
(Supplementary Table S3). 211 
Variables associated with overall mortality and readmission at follow-up 212 
During a mean follow-up period of 6.3±1.0 months, 153 patients (25.0%) died and 189 213 
(30.9%) experienced at least one unplanned hospital readmission; compared with home-214 
discharged patients, MLTCF-discharged patients showed higher mortality (32.1% vs 21.4%) 215 
and a lower readmission rate (24.4% vs 34.3%). All-cause mortality did not differ 216 
significantly among patients with and without PIMs (26% vs 23.9%) and with and without 217 
PPOs (27.3% vs 23.0%). Among patients with at least one PIM, readmission rate was 35.5%, 218 
compared with a 25.4% in those without PIMs (P value .009); unplanned re-hospitalizations 219 
were also significantly higher in patients with at least one PPO than in patients without 220 
(36.7% vs 25.8%, P value .005). Similar findings were observed when PIMs and PPOs were 221 
considered as continuous variables. 222 
Several variables were significantly associated with study outcomes at univariate analysis and 223 
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were included in the multivariate model. Table 2 shows variables independently associated 224 
with mortality and unplanned hospital readmission in the overall sample and according to 225 
discharge setting. In the overall sample and in each discharge setting, PIMs and PPOs 226 
(considered as continuous variables) were not associated with mortality, that was significantly 227 
associated with ADL dependence, cognitive impairment, renal and hepatic comorbidity in the 228 
overall sample. A higher number of PIMs was independently associated with unplanned 229 
hospital readmission (OR 1.23, 95%CI 1.03-1.46), along with a higher number of drugs at 230 
discharge (OR 1.11, 95%CI 1.05-1.18) and renal disease, while MLTCF discharge was 231 
protective (OR 0.64, 95%CI 0.43-0.95). A higher number of PIMs was independently 232 
associated with unplanned readmissions in home-discharged patients (OR 1.38, 95%CI 1.13-233 
1.68), along with renal and cardiac comorbidities. In MLTCF-discharged patients unplanned 234 
readmissions were associated with a higher number of drugs at discharge (OR 1.27 95%CI 235 
1.13-1.42) and the presence of neurological comorbidity (not including dementia). PPOs were 236 
not found to be independently associated with either outcome in the overall sample and in 237 
any subgroup analysis. No significant interaction between specific comorbidities, moderate-238 
severe cognitive impairment, functional dependence  and significant exposures was found. 239 
DISCUSSION 240 
In this prospective study we have evaluated the association of PIMs and PPOs 241 
identified according to STOPP/START v2 in a sample of hospital-discharged older patients, 242 
with a high prevalence of IP, poor general health and functional status, and high post-243 
discharge overall mortality and readmission rate (25.0% and 30.9%, respectively). The main 244 
findings of this study were: 1) PIMs, PPOs and number of drugs at discharge were not 245 
significantly associated with all-cause mortality in the overall study sample and in each 246 
discharge setting; 2) a higher number of PIMs was significantly associated with unplanned 247 
hospital readmission in the overall study sample (OR 1.23, 95%CI 1.03-1.46) and in home-248 
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discharged patients (OR 1.38, 95%CI 1.13-1.68); 3) a higher number of drugs at discharge 249 
was associated with unplanned hospital readmission in the overall study sample (OR 1.11, 250 
95%CI 1.05-1.18) and in MLTCF-discharged patients (OR 1.27, 95%CI 1.13-1.42). 251 
Few studies have investigated the impact of IP according to STOPP/START criteria, 252 
mainly retrospectively and focusing on ADEs and related healthcare use 
20–25
. In a Belgian 253 
prospective study on 503 community-dwellers, PPOs according to START v2 were 254 
consistently associated with mortality and hospitalization at 18 months 
34
. In a recent study, 255 
Fabbietti et al have shown that, among inpatients, polypharmacy (i.e. >8 medications), but 256 
not PIMs according to both Beers 2015 and STOPP v2, was associated with re-hospitalization 257 
at 3 months 
23
. In a retrospective study investigating the impact of STOPP/START v2 in an 258 
inpatient setting, Counter et al have demonstrated that the presence of at least one PIM was 259 
associated with repeated readmissions (OR 2.43, 95%CI 1.19-4.98), while the presence of at 260 
least one PPO was associated with mortality (OR 1.88, 95%CI 1.20-5.28) 
25
. In a prospective 261 
study on 1,753 community-dwellers, the prevalence of PIMs and PPOs were 57% and 41.8%, 262 
respectively, and higher rates of emergency department visits were observed in those with at 263 
least one PIM, or with two or more PPOs 
21
. 264 
At odds with some previous studies 
25,34
, PIMs and PPOs were not significantly 265 
associated with all-cause mortality in both discharge settings. However, the study of Wauters 266 
et al. included community-dwelling subjects with better health and functional status 267 
compared with the patients in our study 
34
, whereas Counter et al retrospectively evaluated 268 
259 hospital-discharged patients with scant clinical data and no CGA 
25
. In a population of 269 
older hospital-discharged patients with high short-term mortality, it is very likely that the 270 
burden of comorbidities and poor health status may reduce the impact of inappropriate 271 
prescribing on hard outcomes such as mortality and unplanned readmissions. Indeed our 272 
findings showed that the most significant predictors of mortality in this population are 273 
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cognitive impairment and  functional dependence, as well as renal and hepatic comorbidities. 274 
In keeping with previous studies 
21,25,34
, we observed that PIMs were associated with 275 
increased hospital readmissions in home-discharged patients. Moreover, when considering 276 
the low, although significant, association between PIMs at discharge and unplanned hospital 277 
readmission, it should be kept in mind that PIMs were included as continuous variables, 278 
highlighting their potentially additional detrimental effect. This association appears to be 279 
consistent also when age-specific prognostic indicators, such as those included in a CGA, and 280 
polypharmacy, are considered. Therefore, although polypharmacy is strongly associated with 281 
IP, it seems not necessarily detrimental per se, at least in these patients, unless it includes 282 
PIMs. The lack of an association between PIMs and re-hospitalization among MLTCF-283 
discharged patients has several potential explanations, including the daily management of 284 
these patients by healthcare professionals, potentially allowing timely therapy adjustments 285 
and local management of ADEs. On the other hand, we observed that the number of drugs 286 
prescribed at discharge, along with concomitant severe neurologic disease, was associated 287 
with increased readmissions in MLTCF-discharged patients. Potential interactions between 288 
the presence of renal, cardiac, hepatic disease, moderate-severe cognitive impairment or 289 
functional dependence and PIMs, PPOs and/or number of drugs at discharge were 290 
specifically investigated but no significant interaction was observed.  291 
Eventually, PPOs were not significantly associated with mortality and unplanned re-292 
hospitalization in the overall sample and in each discharge setting. PPOs should be regarded 293 
as a warning against the risk of omitting disease-specific therapies of proven efficacy in older 294 
patients. However, in a population of older patients, with severe polymorbidity, poor health 295 
status and high prevalence of functional dependence and cognitive impairment, and high 296 
short term mortality, it is rather unlikely that omission of disease-specific drugs may have 297 
clinical implications in patients with high competing risk of mortality.  298 
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The multicenter design of the study, the number of patients enrolled, and the 299 
prospective collection of a full set of clinical variables represent in our view the main 300 
strengths of our study, since they permitted the application of the entire list of STOPP v2 301 
criteria, excluding only a marginal 2.6% of STOPP/START v2 criteria. Moreover, the 302 
systematic evaluation of specific geriatric domains, including frailty, functional and cognitive 303 
statuses through CGA bestows clinical robustness to our findings, by reducing the potential 304 
bias associated with the complex interplay between polypharmacy, comorbidities and health 305 
and functional status. To our knowledge, this methodological approach was not used in most 306 
previous studies. Still, some limitations of our study must be addressed, besides those 307 
specifically pertaining to the application of partially implicit STOPP v2 criteria and the 308 
possible underreporting of significant clinical conditions leading to mislabeling prescriptions 309 
as PIMs 
26
. First, we could not verify the therapeutic compliance of patients or the subsequent 310 
changes made to drug prescription both in the community setting and during subsequent 311 
hospitalizations. However, the short follow-up period makes it unlikely that therapeutic 312 
changes could have biased our results. Moreover, study outcomes were patient- or caregiver-313 
reported and we could not reliably ascertain the cause of death or readmission for many 314 
patients; interviews were standardized and detailed to minimize recall bias. Hence, despite 315 
statistically significant associations, we were not able to define whether re-hospitalizations 316 
were directly due to IP. Therefore, whether PIMs or number of drugs are causally involved in 317 
determining hospital readmissions or act as a surrogate marker of the lack of a careful older 318 
patient-centered discharge plan remains a matter of discussion.  319 
CONCLUSIONS AND IMPLICATIONS 320 
This study adds to the body of evidence demonstrating that IP and polypharmacy are 321 
frequently observed in hospital-discharged patients and may portend a potentially increased 322 
risk of unplanned hospital readmission also in older medical-discharged polymorbid patients. 323 
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Further and larger studies are needed to determine the impact of single PIMs or PPOs on 324 
clinical outcomes, while intervention studies will hopefully confirm the clinical benefit of 325 
addressing IP. 326 
However, our findings suggest once more the importance of performing a systematic 327 
and careful review of medication appropriateness in older in-patients in different clinical 328 
settings, the so-called and long praised “geriatrician’s salute” 35. 329 
Disclosure statement 330 
All authors declare no potential conflict of interest. 331 
REFERENCES 332 
1.  Hamilton HJ, Gallagher PF, O’Mahony D. Inappropriate prescribing and adverse drug 333 
events in older people. BMC Geriatr. 2009;9:5. 334 
2.  Hafner JW, Belknap SM, Squillante MD, Bucheit KA. Adverse drug events in 335 
emergency department patients. Ann Emerg Med. 2002;39:258-267. 336 
3.  Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for 337 
adverse drug events in older Americans. N Engl J Med. 2011;365:2002-2012. 338 
4.  Sona A, Maggiani G, Astengo M, et al. Determinants of recourse to hospital treatment 339 
in the elderly. Eur J Public Health. 2012;22:76-80. 340 
5.  Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in 341 
elderly people. Lancet. 2007;370:185-191. 342 
6.  Steinman MA. Polypharmacy and the balance of medication benefits and risks. Am J 343 
Geriatr Pharmacother. 2007;5:314-316. 344 
7.  Kuijpers MAJ, van Marum RJ, Egberts ACG, Jansen PAF, OLDY (OLd people Drugs 345 
& dYsregulations) Study Group. Relationship between  polypharmacy and  346 
underprescribing. Br J Clin Pharmacol. 2008;65:130-133. 347 
16 
 
8.  Cherubini A, Corsonello A, Lattanzio F. Underprescription of beneficial medicines in 348 
older people: causes, consequences and prevention. Drugs Aging. 2012;29:463-475. 349 
9.  The American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American 350 
Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication 351 
Use in Older Adults. J Am Geriatr Soc. 2015;63:2227-2246. 352 
10.  Spinewine A, Schmader KE, Barber N, et al. Appropriate prescribing in elderly people: 353 
how well can it be measured and optimised? Lancet. 2007;370:173-184.  354 
11.  Bo M, Quaranta V, Fonte G, Falcone Y, Carignano G, Cappa G. Prevalence, predictors 355 
and clinical impact of potentially inappropriate prescriptions in hospital-discharged 356 
older patients: A prospective study. Geriatr Gerontol Int. 2018;18:561-568.  357 
12.  Pasina L, Djade CD, Tettamanti M, et al. Prevalence of potentially inappropriate 358 
medications and risk of adverse clinical outcome in a cohort of hospitalized elderly 359 
patients: results from the REPOSI Study. J Clin Pharm Ther. 2014;39:511-515. 360 
13.  Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahony D. STOPP (Screening Tool of 361 
Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right 362 
Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46:72-83. 363 
14.  O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. 364 
STOPP/START criteria for potentially inappropriate prescribing in older people: 365 
version 2. Age Ageing. 2015;44:213-218.  366 
15.  Hamilton H, Gallagher P, Ryan C, Byrne S, O’Mahony D. Potentially inappropriate 367 
medications defined by STOPP criteria and the risk of adverse drug events in older 368 
hospitalized patients. Arch Intern Med. 2011;171:1013-1019. 369 
16.  Onder G, Landi F, Liperoti R, Fialova D, Gambassi G, Bernabei R. Impact of 370 
inappropriate drug use among hospitalized older adults. Eur J Clin Pharmacol. 371 
2005;61:453-459. 372 
17 
 
17.  Laroche M-L, Charmes J-P, Nouaille Y, Picard N, Merle L. Is inappropriate medication 373 
use a major cause of adverse drug reactions in the elderly? Br J Clin Pharmacol. 374 
2007;63:177-186. 375 
18.  Tosato M, Landi F, Martone AM, et al. Potentially inappropriate drug use among 376 
hospitalised older adults: results from the CRIME study. Age Ageing. 2014;43:767-773.  377 
19.  O’Connor MN, O’Sullivan D, Gallagher PF, Eustace J, Byrne S, O’Mahony D. 378 
Prevention of Hospital-Acquired Adverse Drug Reactions in Older People Using 379 
Screening Tool of Older Persons’ Prescriptions and Screening Tool to Alert to Right 380 
Treatment Criteria: A Cluster Randomized Controlled Trial. J Am Geriatr Soc. 381 
2016;64:1558-1566. 382 
20.  Pérez T, Moriarty F, Wallace E, McDowell R, Redmond P, Fahey T. Prevalence of 383 
potentially inappropriate prescribing in older people in primary care and its association 384 
with hospital admission: longitudinal study. BMJ. 2018;363:k4524. 385 
21.  Moriarty F, Bennett K, Cahir C, Kenny RA, Fahey T. Potentially inappropriate 386 
prescribing according to STOPP and START and adverse outcomes in community-387 
dwelling older people: a prospective cohort study. Br J Clin Pharmacol. 2016;82:849-388 
857.  389 
22.  Wallace E, McDowell R, Bennett K, Fahey T, Smith SM. Impact of Potentially 390 
Inappropriate Prescribing on Adverse Drug Events, Health Related Quality of Life and 391 
Emergency Hospital Attendance in Older People Attending General Practice: A 392 
Prospective Cohort Study. J Gerontol A Biol Sci Med Sci. 2017;72:271-277. 393 
23.  Fabbietti P, Di Stefano G, Moresi R, et al. Impact of potentially inappropriate 394 
medications and polypharmacy on 3-month readmission among older patients 395 
discharged from acute care hospital: a prospective study. Aging Clin Exp Res. 396 
2018;30:977-984. 397 
18 
 
24.  van der Stelt C a. K, Vermeulen Windsant-van den Tweel AMA, Egberts ACG, et al. 398 
The Association Between Potentially Inappropriate Prescribing and Medication-Related 399 
Hospital Admissions in Older Patients: A Nested Case Control Study. Drug Saf. 400 
2016;39:79-87.  401 
25.  Counter D, Millar JWT, McLay JS. Hospital readmissions, mortality and potentially 402 
inappropriate prescribing: a retrospective study of older adults discharged from hospital. 403 
Br J Clin Pharmacol. 2018;84:1757-1763. 404 
26.  Bo M, Gibello M, Brunetti E, et al. Prevalence and predictors of inappropriate 405 
prescribing according to the Screening Tool of Older People’s Prescriptions and 406 
Screening Tool to Alert to Right Treatment version 2 criteria in older patients 407 
discharged from geriatric and internal medicine wards: A prospective observational 408 
multicenter study. Geriatr Gerontol Int. 2019;19:5-11. 409 
27.  von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of 410 
Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting 411 
observational studies. J Clin Epidemiol. 2008;61:344-349.  412 
28.  Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or 413 
more medicines were used to identify community-dwelling older men at risk of different 414 
adverse outcomes. J Clin Epidemiol. 2012;65:989-995. 415 
29.  Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the 416 
aged. The index of ADL: a standardized measure of biological and psychosocial 417 
function. JAMA. 1963;185:914-919. 418 
30.  Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental 419 
activities of daily living. The Gerontologist. 1969;9:179-186. 420 
31.  Pfeiffer E. A short portable mental status questionnaire for the assessment of organic 421 
brain deficit in elderly patients. J Am Geriatr Soc. 1975;23:433-441. 422 
19 
 
32.  Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and 423 
frailty in elderly people. Can Med Assoc J. 2005;173:489-495. 424 
33.  Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc. 425 
1968;16:622-626. 426 
34.  Wauters M, Elseviers M, Vaes B, et al. Too many, too few, or too unsafe? Impact of 427 
inappropriate prescribing on mortality, and hospitalization in a cohort of community-428 
dwelling oldest old. Br J Clin Pharmacol. 2016;82:1382-1392. 429 
35.  Hilmer SN, Gnjidic D. Deprescribing: the emerging evidence for and the practice of the 430 
“geriatrician’s salute.” Age Ageing. 2018;47:638-640. 431 
  432 
20 
 
Figure 1 433 
 434 
 435 
 436 
 437 
 438 
 439 
 440 
 441 
 442 
 443 
 444 
 445 
 446 
 447 
 448 
 449 
 450 
 451 
 452 
 453 
 454 
Study flowchart of patient enrolment and follow-up. 455 
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In-hospital death 
(n=97) 
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Excluded because: 
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- Data incomplete (n=34) 
Patients enrolled 
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Terminally ill (n=49) 
Lost at follow-up (n=66) 
Patients included in the analysis 
(n=611) 
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Table 1 457 
Main clinical and demographic characteristics of the overall study sample, and stratified 458 
according to home or medium/long-term care facility discharge. 459 
 Overall 
sample 
(n=611) 
Home 
discharge 
(n=402) 
MLTCF 
discharge 
(n=209) 
p-value 
Age (years), mean ± SD 81.6±7.0 81.0±7.3 82.6±6.6 .008 
Female sex, n (%) 296 (48.4) 180 (44.8) 116 (55.5) .02 
Geriatric discharge, n (%) 296 (48.4) 173 (43.0) 123 (58.9) < .001 
Serum creatinine (mg/dl), median 
(IQR) 
0.95 (0.75-
1.3) 
1.0 (0.79-
1.3) 
0.86 (0.70-
1.2) 
< .001 
Body weight (kg), median (IQR) 66 (60-74) 68 (60-75) 65 (58-72) .006 
Body weight (kg) for males, 
median (IQR) 
70 (64-76) 70 (65-78) 67 (60-75) .002 
Body weight (kg) for females, 
median (IQR) 
61 (55-70) 62 (55-70) 61 (54-70) .93 
eGFR (ml/min), median (IQR) 50.9 (38.2-
65.8) 
50.2 
(36.5-
64.7) 
52.2 (40.6-
67.5) 
.14 
Provenience     
Home, n (%) 554 (90.7) 399 (99.3) 155 (74.2) 
< .001 
MLTCF, n (%) 57 (9.3) 3 (0.75) 54 (25.8) 
Comprehensive geriatric 
assessment 
    
ADL dependent, n (%) 287 (47) 159 (39.6) 128 (61.2) < .001 
IADL partially or not autonomous, 
n (%) 
436 (71.4) 249 (61.9) 187 (89.5) < .001 
Moderate-severe cognitive 
impairment at SPMSQ, n (%) 
174 (28.5) 77 (19.2) 97 (46.4) < .001 
Frail according to CSHA, n (%) 424 (69.4) 231 (57.5) 193 (92.3) < .001 
Comorbidities     
CIRS severity index, mean ± SD 1.9±0.3 1.89±0.31 1.87±0.25 .38 
CIRS comorbidity index, mean ± 
SD 
4.7±1.6 4.69±1.65 4.73±1.59 .77 
Cardiac, n (%) 403 (66) 273 (67.9) 130 (62.2) .19 
Hypertension, n (%) 413 (67.6) 278 (69.2) 135 (64.6) .29 
Vascular and hematological, n (%) 292 (47.8) 189 (47.0) 103 (49.3) .65 
Respiratory, n (%) 237 (38.8) 158 (39.3) 79 (37.8) .78 
Eye, ear, nose, throat, larynx, n 
(%) 
67 (11) 49 (12.2) 18 (8.6) .23 
Upper gastrointestinal tract, n (%) 104 (17.0) 76 (18.9) 28 (13.4) .11 
Lower gastrointestinal tract, n (%) 59 (9.7) 43 (10.7) 16 (7.7) .29 
Hepatic, n (%) 30 (4.9) 21 (5.2) 9 (4.3) .76 
Renal, n (%) 235 (38.5) 171 (42.5) 64 (30.6) .005 
Other genitourinary, n (%) 167 (27.3) 117 (29.1) 50 (23.9) .21 
Musculoskeletal system and skin, 241 (39.4) 141 (35.1) 100 (47.8) .003 
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n (%) 
Neurological (not including 
dementia), n (%) 
130 (21.3) 69 (17.2) 61 (29.2) < .001 
Endocrine, metabolic and 
infective, n (%) 
289 (47.3) 195 (48.5) 94 (45) .46 
Psychiatric and behavioral 
(including dementia), n (%) 
220 (36.0) 116 (28.9) 104 (49.8) < .001 
Therapy at discharge     
Number of drugs, mean ± SD 7.7±3.2 7.7±3.2 7.6±3.1 .83 
Polypharmacy (≥5 drugs), n (%) 510 (83.5) 337 (83.8) 173 (82.8) .83 
Hyperpolypharmacy (>10 drugs), 
n (%)  
118 (19.3) 77 (19.2) 41 (19.6) .98 
Patients with at least 1 IP, n (%) 438 (71.7) 284 (70.6) 154 (73.7) .49 
IPs per patient, mean ± SD 1.7±1.6 1.6±1.5 1.7±1.8  .11 
IPs per patient, median (IQR) 1 (0-3) 1 (0-3) 1 (0-3) .21 
Patients with at least 1 PIM, n (%) 335 (54.8) 217 (54) 118 (56.5) .62 
PIMs per patient, mean ± SD 0.9±1.1 0.9±1.1 0.9±1.2 .72 
PIMs per patient, median (IQR) 1 (0-2) 1 (0-2) 1 (0-2) .59 
Patients with at least 1 PPO, n (%) 289 (47.3) 184 (45.8) 105 (50.2) .34 
PPOs per patient, mean ± SD 0.7±1 0.7±0.9 0.9±1.2 .03 
PPOs per patient, median (IQR)  0 (0-1) 0 (0-1) 1 (0-1) .16 
 460 
Underlined values indicate statistically significant differences between discharge setting 461 
groups. 462 
Abbreviations: ADL =activities of daily living, CIRS = cumulative illness rating scale, 463 
CSHA = Canadian Study of Health and Aging, eGFR = estimated glomerular filtration rate, 464 
IADL = instrumental activities of daily living, IP = inappropriate prescription, IQR = 465 
interquartile range, n= number, MLTCF = medium-long term care facility, PIM = potentially 466 
inappropriate medication, PPO = potential prescribing omission, SD = standard deviation, 467 
SPMSQ = Short Portable Mental Status Questionnaire 468 
  469 
23 
 
Figure 2 470 
 471 
 472 
 473 
 474 
173 
276 
322 
162 
169 
182 
100 
106 
66 176 
60 41 
0
100
200
300
400
500
600
700
1 2 3
None 1 2 ≥3 
173 
276 
322 
162 169 
182 
100 106 
66 
176 
60 41 
0
50
100
150
200
250
300
350
1 2 3
None 1 2 ≥3 
Commento [EB8]: Qui il reviewer 2 
vorrebbe in colonne invece che in 
torta, posto che lo trovo molto meno 
indicativo, preferisci la versione 1 o 2? 
(colonne IP/PIMS/PPO) 
Commento [EB10]:  
Commento [MB9]: Come preferisci, 
direi forse la seconda, è un deficiente, 
non andiamogli dietro… 
24 
 
Number per patient and prevalence of overall inappropriate prescribing (IP), potentially 475 
inappropriate medications (PIMs) and potential prescribing omissions (PPOs) in the overall 476 
study sample. 477 
  478 
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Table 2 479 
Variables independently associated with overall mortality and hospital readmission at 480 
multivariate analysis in the overall study sample, and according to discharge setting (home vs 481 
medium/long-term care facility). 482 
 OR (95% CI) Coefficient SE p-value 
Overall study sample (n=611) 
Overall mortality 
Female sex 0.64 (0.43-0.95) -0.4489 0.2074 .03 
ADL dependent 2.43 (1.53-3.87) 0.8873 0.2372 < .001 
Renal comorbidity 2.52 (1.67-3.78) 0.9231 0.2080 < .001 
Hepatic comorbidity 2.59 (1.14-5.84) 0.9500 0.4160 .02 
Moderate-severe 
cognitive impairment at 
SPMSQ 
2.54 (1.59-4.07) 0.9339 0.2399 < .001 
Hospital readmission 
Renal comorbidity 1.85 (1.29-2.67) 0.6177 0.1868 < .001 
MLTCF discharge 0.64 (0.43-0.95) -0.4430 0.1995 .03 
Number of drugs at 
discharge 
1.11 (1.05-1.18) 0.1063 0.0309 < .001 
Number of PIMs  1.23 (1.03-1.46) 0.2048 0.0872 .02 
Home-discharged patients (n=402) 
Overall mortality 
Female sex 0.57 (0.34-0.97) -0.5566 0.2666 .04 
ADL dependent 2.24 (1.25-4.00) 0.8050 0.2971 .007 
Renal comorbidity 1.84 (1.11-3.06) 0.6096 0.2587 .02 
Moderate-severe 
cognitive impairment at 
SPMSQ 
2.31 (1.21-4.41) 0.8386 0.3291 .01 
Hospital readmission 
Cardiac comorbidity 1.68 (1.03-2.74) 0.5168 0.2504 .04 
Renal comorbidity 2.38 (1.52-3.71) 0.8651 0.2278 < .001 
Number of PIMs 1.38 (1.13-1.68) 0.3216 0.0999 .01 
MLTCF-discharged patients (n=209) 
Overall mortality 
Renal comorbidity 4.83 (2.37-9.87) 1.5752 0.3645 < .001 
Moderate-severe 
cognitive impairment at 
SPMSQ 
3.96 (1.97-7.95) 1.3758 0.3558 < .001 
Hospital readmission 
Neurological 
comorbidity 
2.37 (1.17-4.81) 0.8642 0.3601 .02 
Number of drugs at 
discharge 
1.27 (1.13-1.42) 0.2382 0.0585 < .001 
 483 
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Abbreviations: ADL = activities of daily living, CI = confidence interval, MLTCF = medium-484 
long term care facility, OR = odds ratio, PIM = potentially inappropriate medication, SE = 485 
standard error, SPMSQ = Short Portable Mental Status Questionnaire 486 
